Kamada - KMDA Stock Forecast, Price & News

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Wall Street Analyst Weigh In

Several research firms have commented on KMDA. StockNews.com began coverage on Kamada in a research report on Monday, August 1st. They issued a "buy" rating on the stock. TheStreet lowered Kamada from a "c-" rating to a "d" rating in a research report on Monday, June 13th.

Kamada Price Performance

Shares of NASDAQ:KMDA traded up $0.11 during midday trading on Monday, reaching $5.28. 24,649 shares of the company's stock traded hands, compared to its average volume of 24,461. Kamada has a 1 year low of $4.22 and a 1 year high of $6.96. The company has a market cap of $235.07 million, a P/E ratio of -35.20 and a beta of 0.98. The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.22 and a current ratio of 2.75. The company has a fifty day simple moving average of $4.70 and a two-hundred day simple moving average of $5.23.

Kamada (NASDAQ:KMDA - Get Rating) last announced its earnings results on Tuesday, May 17th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.07). Kamada had a negative net margin of 6.31% and a negative return on equity of 3.44%. The business had revenue of $28.09 million for the quarter, compared to analysts' expectations of $32.43 million. During the same quarter last year, the business earned $0.06 EPS. Equities analysts predict that Kamada will post -0.07 EPS for the current fiscal year.